GLP-1 Insurance Coverage: The 2026 Update

Insurance coverage for GLP-1 medications has been a moving target since Wegovy's 2021 FDA approval for obesity. Employer plans that covered diabetes GLP-1s balked at adding weight-loss coverage due to cost. Medicare initially excluded weight-loss medications entirely by statute. 2024–2026 brought gradual changes as political and market pressures shifted the landscape.

As of April 2026, here's the clearest picture we can provide.

Commercial insurance: the 2026 state of play

These figures are approximations — exact coverage varies by employer, carrier, and plan type. Self-insured employer plans can exclude GLP-1 coverage entirely regardless of carrier.

Prior authorization: the gatekeeper

Most commercial plans covering GLP-1s require prior authorization. Typical requirements:

For weight-loss indication (Wegovy, Zepbound)

• BMI ≥30, or BMI ≥27 with weight-related comorbidity (diabetes, hypertension, dyslipidemia, sleep apnea, etc.)
• Documentation of prior weight-loss attempts
• Sometimes: 3–6 month trial of structured lifestyle modification required before medication
• Sometimes: failed trial of alternative weight-loss medication (phentermine, topiramate) first
• Re-authorization every 6–12 months with demonstrated weight loss progress

For T2D indication (Ozempic, Mounjaro)

• Documented T2D diagnosis with recent A1C (usually within 6 months)
• Step therapy: metformin trial required unless contraindicated
• Some plans require additional oral agent trial (sulfonylurea or SGLT2) before GLP-1
• Re-authorization annually with continued glycemic benefit

Manufacturer savings programs

For commercially insured patients, these programs layer with insurance coverage:

• Wegovy Savings Card: Up to $225 off per monthly fill for 13 fills. For eligible commercially insured patients with coverage.
• Wegovy Cash Card: For patients with commercial insurance but no Wegovy coverage — reduces cash price.
• Zepbound Savings Card: As little as $25/month for commercially insured patients with coverage. Non-covered eligible patients can reduce cash costs significantly.
• Ozempic Savings Card: As little as $25/month for eligible commercially insured T2D patients.
• Mounjaro Savings Card: Similar structure for T2D patients.

Medicare coverage: the 2027 inflection point

Medicare Part D has historically been prohibited by statute from covering weight-loss medications. This limitation has softened but not fully resolved:

• T2D coverage: Medicare Part D covers Ozempic, Mounjaro, and Rybelsus for T2D indication. Formulary tier varies by plan.
• Weight-loss coverage (2026): Limited. A few Part D plans have added Wegovy coverage; most have not.
• Cardiovascular risk indication: The Wegovy CV risk reduction approval (2024) has opened some Medicare coverage pathways for patients with established CVD, though still limited.
• 2027 changes: White House-negotiated prices for Ozempic and Wegovy take effect on January 1, 2027. Medicare Part D will pay a 71% discounted rate, dramatically expanding access for Medicare beneficiaries.

Medicare beneficiaries in 2026 with T2D generally have access to GLP-1 coverage. Those without T2D will see major improvements starting 2027.

Medicaid coverage

Medicaid coverage varies dramatically by state:

• T2D coverage: Most state Medicaid programs cover Ozempic and Mounjaro for T2D.
• Weight-loss coverage: Approximately 15 states cover Wegovy for obesity under Medicaid; others don't.
• Prior authorization: Almost universal on state Medicaid programs.

Check your specific state's Medicaid formulary for current coverage.

ACA marketplace plans

ACA (Affordable Care Act) marketplace plans vary by state and carrier. Metal tier matters:

• Gold and Platinum plans: Usually cover GLP-1s with standard prior authorization.
• Silver plans: Coverage varies; many cover T2D medications only.
• Bronze plans: Coverage less common, higher deductibles mean significant out-of-pocket even when covered.
• Catastrophic plans: Minimal coverage typically.

Self-insured employer plans

About 65% of employer health plans are self-insured, meaning the employer (not an insurance company) pays claims. These plans:

• Can add or drop GLP-1 coverage at renewal
• Often set stricter prior authorization requirements due to cost concerns
• May cover diabetes GLP-1s but specifically exclude weight-loss use
• Are outside state insurance regulation (covered by federal ERISA)

If your employer is self-insured and doesn't cover GLP-1s for weight loss, advocacy with HR or benefits committees sometimes produces changes during open enrollment.

VA and military coverage

• VA: Covers Ozempic and Mounjaro for T2D. Wegovy coverage variable by VA medical center and clinical indication.
• Active duty TRICARE: T2D coverage generally available. Weight-loss coverage more limited.
• Military health system patients often have access through MTF pharmacies at significantly reduced cost.

What's coming in 2026–2027

• Medicare negotiated prices (Jan 2027): 71% discount on Ozempic and Wegovy effective.
• Orforglipron approval (late 2026 expected): Lilly's oral tirzepatide-class medication. Likely cheaper than injectable; insurance coverage patterns unclear.
• Continued employer plan additions: Competition among insurers and carriers continues to push coverage expansion.
• State-level mandates: A few states considering legislation to require commercial plans to cover obesity medications.
• Medicare Part B possibility: Potential pathway for Medicare coverage via Part B (medical benefit rather than drug benefit) being discussed.

Strategic advice for 2026

1. Check your formulary first. Don't assume. Call your insurance or check the portal.
2. Understand your PA requirements. Get the paperwork needs clear before your first appointment.
3. Pick providers who do PA work. LifeMD and WeightWatchers Med+ specifically handle this well.
4. Layer savings cards. Manufacturer programs + insurance coverage + provider-specific discounts can produce dramatic savings.
5. Appeal denials. 30% of initial denials get reversed. Document medical necessity comprehensively.
6. Consider PCP coordination. Your own doctor submitting prior auth is often more effective than telehealth providers.
7. Plan for long-term coverage. Year 1 coverage doesn't guarantee year 3. Understand renewal requirements.

Bottom line

In 2026, GLP-1 insurance coverage is better than it's ever been but still leaves significant gaps — especially for Medicare beneficiaries without T2D and for patients with self-insured employer plans that exclude weight-loss medications. The right strategy varies by plan, indication, and provider. Coverage is expanding annually; what's not covered today may be covered next year. For now: know your specific plan, document medical necessity, and use providers who actively pursue prior authorizations rather than defaulting to cash-pay.